CD22 and acute lymphoblastic leukemia: BALLI-01 is an open-label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in patients with R/R CD22+ B-ALL [52].